Arca
Skip to content
Tools
Tools

Gaucher disease

Drug research and approvals for gaucher disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 25 studies of gaucher disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 6 approved and 17 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 25
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 6
  • EU medicines: 7

Recruiting now

Newest posted first, of 25 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 2

Phase 2 6

Phase 1 or earlier 2

How its trials ended

158 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 37 whose ending is known, 57% met their primary endpoint, 3% missed it and 41% stopped early.

  • Completed, result not reported6340%
  • Ongoing4126%
  • Met its primary endpoint2113%
  • Status unknown1711%
  • Stopped: other or unclear117%
  • Stopped: enrollment or feasibility21%
  • Stopped: sponsor or business decision21%
  • Missed its primary endpoint11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 10, 2026Phase 3, open-label, long term extension basket study of venglustat in adult and pediatric patients with Gaucher type 3 disease and adult patients with Fabry…Venglustat (GZ/SAR402671)Sanofi-Aventis Canada IncPending
Dec 23, 2025A phase 3 safety and efficacy trial of FLT201 gene therapy in patients with Gaucher disease type 1FLT201Spur Therapeutics LimitedOngoing
Feb 14, 2022A phase 3, multicenter, multinational, randomized, doubleblind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in…Venglustat (SAR402671) / ImigluceraseSanofi-Aventis Canada IncOngoing
Dec 15, 2020A three-part study to evaluate the efficacy and safety of venglustat in combination with cerezyme in adult and pediatric patients with Gaucher disease type 3…Venglustat (SAR402671)Sanofi-Aventis Canada IncPending
Sep 28, 2018An adaptive, open-label, multinational phase 1/2 study of the safety and efficacy of ex vivo, lentiviral vector-mediated gene therapy AVR-RD-02 for subjects…AVR-RD-02AVROBIOOngoing
Oct 2, 2017Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics (PK), safety, and efficacy of eliglustat in pediatric…Cerdelga (eliglustat)SanofiClosed
Jun 9, 2015Open label interventional multicenter phase 3b study to evaluate skeletal response to eliglustat in adult patients who successfully completed the phase 2 or…Cerdelga (eliglustat)SanofiClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 23
Jan 12, 2026CerezymeTreatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patientsGenzyme CorporationApproved
Aug 19, 2014CerdelgaLong-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers…Genzyme CorporationApproved
May 1, 2012ELELYSO for injectionUse as long-term enzyme replacement therapy in patients with Type 1 Gaucher diseasePfizer, Inc.Approved
Feb 26, 2010VprivTreatment of Type I Gaucher DiseaseTakeda Development Center Americas, Inc.Approved
Jul 31, 2003ZavescaTreatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due…IC-MedTech CorporationApproved
Apr 5, 1991CeredaseLong-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who…Genzyme CorporationApproved
Aug 24, 2026AmbroxolTreatment of Gaucher diseaseLILA Holding AGDesignated
Apr 10, 2026Selective glucosylceramide synthase (GCS) inhibitorTreatment of Gaucher diseaseYuhan CorporationDesignated
Jan 13, 2026Adeno-associated viral vector delivering human GBA1 geneTreatment of Gaucher diseaseShanghai Vitalgen BioPharma Co., Ltd.Designated
Jun 10, 2025AmbroxolTreatment of Gaucher diseaseKalevala Therapeutics Inc.Designated
Apr 16, 2025AmbroxolTreatment of Gaucher disease (GD)Agyany Pharma LTD.Designated
Sep 9, 2024Adeno-associated virus 9 vector expressing a functional…Treatment of Gaucher DiseaseNational Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)Designated
Oct 5, 2023Recombinant adeno-associated virus (rAAV)Treatment of Gaucher diseaseLingyi Biotech Co. Ltd.Designated
Sep 2, 2021Eliglustat TartrateTreatment of Gaucher Disease Type 1 patients who are CYP2D6 ultra-rapid metabolizers and patients whose CYP2D6 genotype cannot be…Amneal Pharmaceuticals LLCDesignated
Aug 11, 2021Recombinant adeno-associated viral vector serotype S3…Treatment of Gaucher DiseaseSpur Therapeutics LimitedDesignated

Medicines authorised in the EU

Newest first
Feb 18, 2019Miglustat DipharmaMiglustat · genericDipharma Arzneimittel GmbHEMA ↗
Nov 9, 2017Veanibek (previously Miglustat Gen.Orph)Miglustat · genericGen.OrphEMA ↗
Mar 22, 2017YargesaMiglustat · genericPiramal Critical Care B.V.EMA ↗
Jan 19, 2015CerdelgaEliglustat · orphanSanofi B.V.EMA ↗
Aug 26, 2010VprivVelaglucerase alfaTakeda Pharmaceuticals International AG Ireland BranchEMA ↗
Nov 20, 2002ZavescaMiglustatAdvanz Pharma LimitedEMA ↗
Nov 17, 1997CerezymeImigluceraseSanofi B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.